Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021)
Castle Biosciences (CSTL) posted Current Deferred Revenue of $3.0 million for Q3 2021, down 51.45% sequentially from $6.2 million in Q2 2021, and down 64.08% YoY from $8.4 million in Q3 2020.
Castle Biosciences (CSTL) Current Deferred Revenue (2020 - 2021) Analysis & Trends
Castle Biosciences (CSTL) has 2 years of Current Deferred Revenue data on file, last reported at $3.0 million in Q3 2021.
- Quarterly Current Deferred Revenue fell 64.08% year-over-year to $3.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $3.0 million (down 64.08% YoY) and the FY2020 annual result came in at $6.6 million, changed N/A from the prior year.
- Current Deferred Revenue slipped to $3.0 million in Q3 2021 per CSTL's latest filing, from $6.2 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $8.4 million in Q2 2020, with the low at $3.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Waters | 31,055.11 Bn | 31,054.65 Bn | 1.11 Bn |
| 2 | Thermo Fisher Scientific | 191.02 Bn | 187.77 Bn | 7.74 Bn |
| 3 | Danaher | 137.16 Bn | 131.47 Bn | 3.59 Bn |
| 4 | Idexx Laboratories | 42.82 Bn | 42.62 Bn | 722.74 Mn |
| 5 | Natera | 39.09 Bn | 37.99 Bn | 696.04 Mn |
| 6 | Agilent Technologies | 37.61 Bn | 35.81 Bn | 990.00 Mn |
| 7 | Iqvia Holdings | 34.23 Bn | 32.25 Bn | 1.36 Bn |
| 8 | Illumina | 28.14 Bn | 26.98 Bn | 721.00 Mn |
| 9 | Mettler Toledo International | 26.40 Bn | 26.33 Bn | 555.82 Mn |
| 10 | Castle Biosciences | 738.56 Mn | 476.84 Mn | 63.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 3.00 Mn |
| Jun 30, 2021 | 6.18 Mn |
| Mar 31, 2021 | 8.18 Mn |
| Dec 31, 2020 | 6.62 Mn |
| Sep 30, 2020 | 8.35 Mn |
| Jun 30, 2020 | 8.35 Mn |